Bupivacaine

Q: What is Bupivacaine linked with?

Studies link Bupivacaine with 1 measure, most often major complications (1 study).

Bupivacaine has been studied in 4 papers since 2016: 2 trials in people, 1 in cells, 1 review. The newest paper, Oct 21, 2025: “Surgical site injection of liposomal bupivacaine reduces 90-day incidence of major complications after hip fracture: a nonrandomized trial”.

Intervention

4 papers study it6 more mention it4 findingsUpdated Oct 21, 2025

PubChem ChEBI MeSH

See all 10

“Patients in the LB group had a reduced incidence of major complications within 90 days [19 (14.2%) patients vs. 167 (24.6%) patients] compared with patients in the control group, with an adjusted hazard ratio (HR) of 0.55 [95% confidence interval (CI) 0.34-0.89, P = .014].”

Surgical site injection of liposomal bupivacaine reduces 90-day incidence of major complications after hip fracture: a nonrandomized trialInternational journal of surgery (London, England)2025doi:10.1097/js9.0000000000003808

2 of its findings point the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

2 independent labs in 2 countries
2 findings against
25 trials, none about aging, 3 with no results posted

Funders: Glenn Foundation for Medical Research and 8 more

Human trial2
Cells1

Studies in people

1 study gave bupivacaine to people and measured what changed.

down: Lowers the risk of major complicationsadjusted HR 0.55 (95% CI 0.34-0.89), 14.2% vs 24.6%
no change: Has no effect on mortalityHR 0.74 (0.35-1.56), 6.0% vs 8.5%
up: Improves weight bearingOR 2.40 (1.64-3.51), 54.5% vs 33.1%
Trialaged 65 years or older90 postoperative days
Older adults; after hip fracture surgery
International journal of surgery (London, England), Oct 21, 2025

What did lifespan studies of Bupivacaine find?

DrugAge

DrugAge records 4 results from 1 paper: 2 in C. elegans and 2 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of Bupivacaine find?

Studies of Bupivacaine measured 3 outcomes; the most studied are delirium (1 study), weight bearing (1) and mortality (1).

Delirium

no changein humans1

1 study

Bupivacaine has no effect on delirium in humans (4.5% vs 7.2%, P = 0.254).
“The incidence of delirium was similar between the two group [LB group 6 patients (4.5%) vs. control group 49 (7.2%) patients, P = 0.254].”
Human trialafter hip fracture surgerywithin 7 postoperative days
Surgical site injection of liposomal bupivacaine reduces 90-day incidence of major complications after hip fracture: a nonrandomized trial
International journal of surgery (London, England)Oct 21, 2025

What is Bupivacaine linked with?

Studies link Bupivacaine with 1 measure, most often major complications (1 study).

Major complications

downin humans1HR 0.55

1 study

Bupivacaine lowers the risk of major complications in humans (adjusted HR 0.55 (95% CI 0.34-0.89), 14.2% vs 24.6%).
“Patients in the LB group had a reduced incidence of major complications within 90 days [19 (14.2%) patients vs. 167 (24.6%) patients] compared with patients in the control group, with an adjusted hazard ratio (HR) of 0.55 [95% confidence interval (CI) 0.34-0.89, P = .014].”
Human trialafter hip fracture surgery90 postoperative days
Surgical site injection of liposomal bupivacaine reduces 90-day incidence of major complications after hip fracture: a nonrandomized trial
International journal of surgery (London, England)Oct 21, 2025